• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Prostate cancer >Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity
【24h】

Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity

机译：前列腺癌高危人群中剂量递增的超分割强度调节放疗：结果和晚期毒性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. The benefit of dose-escalated hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) in prostate cancer is not established. We report 5-year outcome and long-term toxicity data within a phase II clinical trial.Materials and Methods. 60 men with predominantly high-risk prostate cancer were treated. All patients received neoadjuvant hormone therapy, completing up to 6 months in total. Thirty patients were treated with 57 Gy in 19 fractions and 30 patients with 60 Gy in 20 fractions. Acute and 2-year toxicities were reported and patients followed longitudinally to assess 5 year outcomes and long-term toxicity. Toxicity was measured using RTOG criteria and LENT/SOMA questionnaire.Results. Median followup was 84 months. Five-year overall survival (OS) was 83% and biochemical progression-free survival (bPFS) was 50% for 57 Gy. Five-year OS was 75% and bPFS 58% for 60 Gy. At 7 years, toxicity by RTOG criteria was acceptable with no grade 3 or above toxicity. Compared with baseline, there was no significant change in urinary symptoms at 2 or 7 years. Bowel symptoms were stable between 2 and 7 years. All patients continued to have significant sexual dysfunction.Conclusion. In high-risk prostate cancer, dose-escalated hypofractionated radiotherapy using IMRT results in encouraging outcomes and acceptable late toxicity.
机译：背景。使用强度调节放疗（IMRT）在前列腺癌中进行剂量递增的超分割放疗的益处尚未确立。我们在II期临床试验中报告了5年的结果和长期毒性数据。材料和方法。治疗了60位以高危前列腺癌为主的男性。所有患者均接受了新辅助激素治疗，总共长达6个月。 30例患者接受19馏分的57 Gy治疗，30例患者接受20馏分的60 Gy治疗。报告了急性和2年毒性，患者纵向随访以评估5年结局和长期毒性。使用RTOG标准和LENT / SOMA问卷测量毒性。中位随访时间为84个月。 57 Gy的五年总生存（OS）为83％，无生化无进展生存（bPFS）为50％。 60 Gy的五年OS为75％，bPFS为58％。在7年时，按照RTOG标准进行的毒性可接受，没有3级或以上的毒性。与基线相比，第2年或第7年的泌尿症状无明显变化。肠症状在2至7岁之间稳定。所有患者均继续存在明显的性功能障碍。在高危前列腺癌中，使用IMRT进行剂量递增的超分割放疗会导致令人鼓舞的结果和可接受的晚期毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号